DocGo said it “categorically rejects this purported assessment by Fuzzy Panda Research, an obscure short seller motivated solely by profit.” The company added in a press release: “The company’s revenue for fiscal year 2023 is expected to be between $615M and $625M, in line with the company’s previously released guidance. DocGo further expects revenue in 2024 to exceed $700M. More specific guidance will be provided when the company releases its Q4 2023 and full year 2023 results in February.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DCGO:
- TipRanks ‘Perfect 10’ List: These 2 Top-Scoring Stocks Are Flirting With a Bottom
- 3 Best Stocks to Buy Now, 12/29/2023, According to Top Analysts
- 3 Best Stocks to Buy Now, 12/19/2023, According to Top Analysts
- 3 Best Stocks to Buy Now, 12/7/2023, According to Top Analysts
- 3 Best Stocks to Buy Now, 6/12/2023, According to Top Analysts